An
*
*insulinoma|302822000
*
*
is
a tumor|108369006
of the pancreas|15776009|181277001
that
is
derived
from beta cells|36565008
and
secretes
insulin.|412222002

Beta cells|36565008
secrete
insulin|412222002
in response
to increases|260366006
in blood glucose.|33747003

The resulting increase|42752001|260366006
in insulin|412222002
acts
to
lower|261122009
blood glucose|33747003
back
to normal levels|17621005|258395000|258744000|258395000
at which
point
further secretion|46053002|46242002
of insulin|412222002
is
stopped.|385654001

In contrast,
the secretion|46242002
of insulin|412222002
by insulinomas|302822000
is
not properly
regulated
by glucose|67079006|72191006
and
the tumors|108369006
will
continue|255238004
to
secrete
insulin causing glucose levels to|16890009|23981006|67079006|16890009|23981006|72191006|412222002|23981006|365811003
fall|1912002
further|46053002
than normal.|17621005|258744000

As a result patients|394617004|116154003
present|52101004|246105001
with symptoms
of low blood glucose|271327008
(hypoglycemia,|271327008
which
are
improved|385425000|3442003
by eating.|48263008

The diagnosis|439401001
of an insulinoma|302822000
is
usually
made
biochemically
with low blood glucose,|271327008
elevated insulin,|75540009|412222002
proinsulin|79212006
and
C-peptide levels|88705004
and
confirmed|59156000
by localizing|255471002
the tumor|108369006
with medical imaging|278395004
or
angiography.|77343006

The definitive treatment|261002007|276239002|261002007|416118004
is
surgery.|83578000

Insulinomas|302822000
are
rare neuroendocrine tumours|84638005|255046005|103356009|255046005
with an incidence
estimated|414135002
at 1
to 4 new cases|260308009|7147002|398241000|260308009|7147002|413769002
per million persons|125676002
per year.|258707000|259039008

Insulinoma|302822000
is
one|421379005
of the most common types|4757001|72906007|261664005
of tumor arising|108369006|68727004
from the islets
of Langerhans cells|76322003
(pancreatic endocrine tumors|126864006
).

Estimates|414135002
of malignancy|363346000|372087000
(metastases|128462008
)
range
from 5%|264706000|264605009
to 30%.

Over 99%
of insulinomas|302822000
originate
in the pancreas,|15776009|181277001
with rare cases|84638005|398241000|84638005|413769002|103356009|398241000|103356009|413769002
from ectopic pancreatic tissue.|264304000

About 5%|264706000|264605009
of cases|398241000|413769002
are
associated|47429007
with tumours|108369006
of the parathyroid glands|111002
and
the pituitary|56329008|58805000
(Multiple endocrine neoplasia type 1|30664006
and
are
more likely to|242762006|2931005
be
multiple|260396001
and
malignant.|21594007

Most insulinomas|302822000
are
small, less|255507004
than 2 cm.|260306008

Patients|116154003
with insulinomas usually|302822000
develop
neuroglycopenic symptoms.|237631006

These
include|55919000
recurrent headache,|255227004|25064002
lethargy,|214264003
diplopia,|24982008
and
blurred vision,|246636008
particularly
with exercise|61686008
or
fasting.|16985007

Severe hypoglycemia|24484000|271327008
may
result|394617004
in seizures,|91175000
coma,|371632003|405809000
and
permanent neurological damage.|6934004|128239009

Symptoms
resulting|42752001
from the catecholaminergic response
to hypoglycemia|271327008
(i.e.|42146005|22971001

tremulousness,|267079009
palpitations,|80313002
tachycardia,|3424008|6285003
sweating|161857006
,
hunger,|55350005
anxiety,|48694002|197480006
nausea|422587007
)
are
not
as common.|72906007

Sudden weight gain|255363002|262286000
(
the patient|116154003
can
become
massively obese|46998006|414915002
)
is
sometimes
seen.

The diagnosis|439401001
of insulinoma|302822000
is
suspected|415684004
in a patient|116154003
with symptomatic fasting hypoglycemia.|264931009|6974005

The conditions|260905004
of Whipple?s triad
need|410525008|103325001
to
be
met|229057006
for the diagnosis|439401001
of "true hypoglycemia" to|31874001|271327008
be
made
:

The following blood tests|255260001|252275004
are
needed|410525008|103325001
to
diagnose|439401001
insulinoma|302822000
:

If available,|103328004
a proinsulin level|79212006|258395000|79212006|276625007
might
be
useful
as well.|20572008

Other blood tests|74964007|252275004
may
help
rule|10828004
out other conditions|255529000|260905004
which
can
cause|23981006|134198009
hypoglycemia.|271327008

Normally,
endogenous insulin production|73979006|412222002
is
suppressed|245780008
in the setting
of hypoglycemia.|271327008

A 72-hour fast,|123028004|16985007|123028004|277748003
usually
supervised
in a hospital setting,|285201006
can
be
done
to
see|281004000
if insulin levels|16890009
fail
to
suppress|245780008
,
which
is
a strong indicator|260404005
of the presence|386397008
of an insulin-secreting tumour.|412222002|108369006

The insulinoma|302822000
might
be
localized|255471002
by non-invasive means,|22762002|255586005
using|260676000
ultrasound,|359659005
CT scan,|77477000
or
by MRI techniques.|113091000|272394005

An Indium-111 pentetreotide scan|56609000|395824006|373205008|56609000|395824006
is
more sensitive|242762006|83185005
than ultrasound,|359659005
CT,
or
MRI|113091000
for detection
of somatostatin receptor positive tumors.|49722008|116647005|258758003|108369006|49722008|116647005|10828004|108369006

Sometimes,
angiography|77343006
with percutaneous transhepatic pancreatic vein catheterization to|103388001|103381007|8059004|45211000|103388001|103381007|264492008|45211000|103388001|103381007|15776009|392230005|103388001|8059004|45211000|103388001|264492008|45211000|103388001|15776009|392230005
sample|123038009
the blood|87612001|119273009
for insulin levels|16890009
is
required.

Calcium|5540006
can
be
injected|422145002
into selected arteries to|51114001|11527006
stimulate
insulin release|412222002|58000006|412222002|68776005|412222002|258760001|412222002|129299003|412222002|115956009
from various parts|256220008|260726005
of the pancreas,|15776009|181277001
which
can
be
measured|258104002
by sampling blood|257915005|87612001|257915005|119273009
from their respective veins.|29092000

The use|277889008|419385000
of calcium stimulation|5540006|122545008
improves|385425000|3442003|385633008
the specificity|69658003
of this test.|269814003|272393004

During surgery to|83578000
remove|127485006
an insulinoma,|302822000
an intra-operative ultrasound|277671009|359659005|272114000|257886002
can
sometimes
localize|255471002
the tumour,|108369006
which
helps
guide|106384005|303479009
the surgeon|304292004
in the operation|83578000
and
has
a higher sensitivity|75540009|35209006|75540009|365705006|371879000|35209006|371879000|365705006
than noninvasive imaging tests.|22762002|363679005|269814003|22762002|363679005|272393004|22762002|278395004|269814003|22762002|278395004|272393004

The definitive management|261002007|413454004|261002007|119270007
is
surgical removal|118292001|128303001|128304007
of the insulinoma.|302822000

This
may
involve|248448006
removing|127485006
part|260726005
of the pancreas|15776009|181277001
as well|20572008
(Whipple procedure|116241004
and
distal pancreatectomy.|401004

Most patients|116154003
with benign insulinomas|30807003|302822000
can
be
cured
with surgery.|83578000

Persistent
or
recurrent hypoglycemia|255227004|271327008
after surgery|83578000
tends
to
occur|272120004
in patients|116154003
with multiple tumours.|369755005

About two percent|420797005|118582008
of patients|116154003
develop
diabetes mellitus|73211009
after their surgery.|83578000

Hypoglycemia|271327008
was
first|255216001|232714002
recognized
in the 19th century.

In the 1920s,
after
the discovery
of insulin|412222002
and
its use|277889008|419385000
in the treatment|276239002|416118004
of diabetics,
hyperinsulinism|83469008
was
suspected|415684004
to
be
a cause|134198009
of hypoglycemia|271327008
in non-diabetics.

The first report|255216001|229059009|255216001|223458004|232714002|229059009|232714002|223458004
of a surgical cure|83578000
of hypoglycemia|271327008
by removing|127485006
an islet cell tumour|126864006
was
in 1929.

M
:
END|261782000|422117008

anat/phys/devp/horm

noco
(d/cong/tumr,|876000
sysi/epon

proc,
drug|410942007
(A10/H1/H2/H3/H5

